See more : Gerdau S.A. (GGBR3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Sana Biotechnology, Inc. (SANA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sana Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ManpowerGroup Inc. (MAN) Income Statement Analysis – Financial Results
- Rashtriya Chemicals and Fertilizers Limited (RCF.NS) Income Statement Analysis – Financial Results
- Bausch + Lomb Corporation (BLCO) Income Statement Analysis – Financial Results
- Chase Mining Corporation Limited (CML.AX) Income Statement Analysis – Financial Results
- Suminoe Textile Co., Ltd. (3501.T) Income Statement Analysis – Financial Results
Sana Biotechnology, Inc. (SANA)
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| Gross Profit | -30.87M | -27.73M | -17.91M | -10.17M | -3.92M | -1.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.64M | 201.00M | 306.50M | 257.88M | 119.38M | 4.01M |
| General & Administrative | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 8.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.21M |
| SG&A | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 4.21M |
| Other Expenses | 0.00 | -674.00K | 305.00K | 97.00K | -29.00K | 0.00 |
| Operating Expenses | 294.94M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Cost & Expenses | 325.81M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Interest Income | 9.94M | 3.76M | 676.00K | 747.00K | 2.86M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| EBITDA | -252.39M | -256.94M | -356.91M | -287.03M | -138.90M | -13.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -326.90M | -272.56M | -356.91M | -286.15M | -141.15M | -8.22M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 43.65M | 3.09M | 981.00K | 844.00K | 2.83M | -5.03M |
| Income Before Tax | -283.26M | -269.48M | -355.93M | -285.31M | -138.33M | -13.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.09M | -11.75M | -6.67M | -7.55M | 0.00 |
| Net Income | -283.26M | -266.39M | -344.18M | -278.64M | -130.78M | -13.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| EPS Diluted | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| Weighted Avg Shares Out | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Weighted Avg Shares Out (Dil) | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sana Biotechnology Announces Pricing of Upsized Public Offering
Sana Biotechnology Announces Proposed Public Offering of Common Stock
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
JD Henning Cautious About 2024, An Unusual Year For Market Considerations
Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports